Nimble Therapeutics, Madison, Wis, is collaborating with Roche Diagnostics, Basel, Switzerland, to accelerate discovery of novel peptide-based molecules for the development of SARS-CoV-2 in vitro diagnostics.
Nimble will extend its proprietary peptide synthesis, screening, and optimization platform to enable faster discovery and optimization of promising compounds for detecting SARS-CoV-2. Roche will leverage its world-class capabilities to develop in vitro diagnostics for rapid detection of SARS-CoV-2.
“We are extremely motivated to partner with Roche to tackle this global covid-19 health crisis,” says Jigar Patel, PhD, chief executive officer at Nimble Therapeutics. “This partnership expands our discovery capabilities, demonstrating the power and breadth of the Nimble platform in rapidly discovering novel compounds.”
For more information, visit Nimble Therapeutics.
